Welcome to our dedicated page for Siga Technologie SEC filings (Ticker: SIGA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SIGA Technologies, Inc. (SIGA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, annual reports on Form 10-K, quarterly reports on Form 10-Q, and related exhibits that together describe SIGA’s financial condition, business activities, and material events.
Recent Form 8-K filings by SIGA have reported the release of quarterly financial results, incorporating press releases that summarize product sales, total revenues, operating income or loss, and net income or loss for specific periods. These filings give context on the commercial performance of TPOXX (tecovirimat), including revenues from oral and IV formulations and the impact of deliveries to the U.S. Strategic National Stockpile and international customers.
Through its periodic reports, SIGA also discloses research and development revenues, cost of sales, selling, general and administrative expenses, and research and development expenses. The company’s filings discuss its contracts with U.S. government agencies such as BARDA, including development funding for pediatric programs and manufacturing support related to TPOXX, as well as broader risk factors tied to government contracts, regulatory approvals, intellectual property, and supply chain considerations.
On Stock Titan, these SEC filings are updated as they are made available on EDGAR. AI-powered summaries help explain the key points of lengthy documents, such as 10-K and 10-Q reports, by highlighting items like revenue composition, operating results, and significant contract or regulatory developments. Users can also review Form 8-K disclosures for material events, including earnings announcements and capital management decisions such as special cash dividends.
This page is a resource for investors and researchers who want to understand how SIGA describes its business, financial results, government relationships, and risk profile in its official SEC filings, with AI tools that make complex regulatory documents easier to interpret.
SIGA Technologies describes its biodefense-focused pharmaceutical business built around TPOXX, an antiviral for smallpox and related orthopox viruses, sold mainly to governments. The company’s core U.S. revenue base is a BARDA contract contemplating up to approximately
SIGA also reports sales to the U.S. Department of Defense of about
The filing highlights regulatory risk: European and U.K. approvals for Tecovirimat‑SIGA were granted under “exceptional circumstances” and are undergoing annual reassessment after mpox trials (PALM007, STOMP, UNITY) failed to show statistically significant efficacy on primary endpoints. The CHMP is expected to decide in March whether to maintain, modify, suspend, or withdraw indications, which could reduce mpox‑related revenue. SIGA notes a broad global patent estate on TPOXX with key protections extending into the 2030s and an employee base of 49 as of February 13, 2026.
SIGA Technologies reported sharply lower results for 2025 but remained profitable. Total revenues were $94.6 million, down from $138.7 million in 2024, as product sales declined to $88.0 million from $133.3 million. Net income fell to $23.3 million, with diluted earnings per share of $0.32 versus $0.82 a year earlier.
Management highlighted $27 million of additional U.S. government funding secured in 2025 to support development and a $13 million oral TPOXX procurement order from an Asia Pacific customer received in January 2026. The balance sheet showed $154.9 million in cash and cash equivalents as of December 31, 2025 and total stockholders’ equity of $198.8 million.
SIGA Technologies Chief Executive Officer Diem Nguyen reported equity compensation activity involving restricted stock units and common shares. On January 27, 2026, 55,902 restricted stock units vested and converted into the same number of common shares at an exercise price of
To cover tax withholding related to this vesting, the issuer withheld 22,804 common shares at
SIGA Technologies (SIGA) reported Q3 2025 results showing lower quarterly activity amid timing of product deliveries. Revenue was $2.62 million, down from $10.01 million a year ago, with no point‑in‑time product delivery recognized in the quarter and $1.73 million from research and development services.
The quarter posted a net loss of $6.37 million versus net income of $1.34 million last year, reflecting higher self‑funded R&D and lower sales. Year to date, performance remains strong: nine‑month revenue was $90.78 million (vs. $57.25 million) and net income was $28.71 million (vs. $13.45 million). Cash and cash equivalents were $171.96 million as of September 30, 2025, after paying a $0.60 per share special dividend on May 15, 2025.
Under the 19C BARDA Contract, the company cites up to approximately $630 million of contemplated payments, with $79.1 million of 2025 revenue recognized at a point in time through September 30. The EMA initiated a referral to review Tecovirimat‑SIGA following mixed mpox trial readouts; approvals in other markets remain as stated. As of October 24, 2025, 71,611,302 shares were outstanding.
SIGA Technologies, Inc. filed a current report to note that it has released its financial results for the quarter ended September 30, 2025. On November 6, 2025, the company issued an earnings press release describing its quarterly performance, which is furnished as Exhibit 99.1 to this report and incorporated by reference. The information in this earnings item is furnished rather than filed under securities law, which affects how related liabilities and future references apply.
Form 4 filing overview – SIGA Technologies, Inc. (SIGA)
Executive Vice President & Chief Scientific Officer Dennis E. Hruby reported routine equity transactions dated July 1 2025.
- RSU vesting (Code M): 32,258 restricted stock units converted to common shares at a cost basis of $0.00.
- Share withholding for taxes (Code F): 10,467 shares automatically sold/withheld at $6.49 per share to satisfy statutory tax obligations.
- Net share change: +21,791 shares, increasing direct ownership to 191,047 common shares.
- The underlying RSU grant was issued on May 11 2023 and vested 50 % on July 1 2024 and the remaining 50 % on July 1 2025; no derivative units remain outstanding after this conversion.
The filing reflects standard incentive-plan vesting mechanics rather than open-market buying or discretionary selling.